ASX Share rice
Thu 13 Aug 2020 - 09:07:am (Sydney)

RNO Share Price

RHINOMED LIMITEDRNOPharmaceuticals, Biotechnology & Life Sciences

RNO Company Information

Name:

Rhinomed Limited

Sector:

Healthcare

Industry:

Medical Appliances & Equipment

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

132 Gwynne Street Richmond VIC Australia 3121

Phone:

61 3 8416 0900

CEO, MD & Exec. Director:

Mr. Michael Johnson

CFO & Company Sec.:

Mr. Sean Slattery

Company Overview:

Rhinomed Limited, a nasal medical technology and drug delivery company, engages in the research, development, and commercialization of consumer and medical devices worldwide. The company identifies, acquires, and commercializes late stage therapeutic delivery technologies. Its product portfolio includes Turbine, a nasal dilator designed to assist to breathe easier during aerobic exercise; Mute, a nasal dilator designed to enhance airflow and reduce snoring while sleep; and Pronto, a nasal dilator to open nose and improve airflow. The company sells its products through wholesalers, retail stores, and clinics, as well as online. It serves clinicians and health care organizations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.

RNO Share Price Information

Shares Issued:

169.21M

Market Capitalisation:

$13.87M

Revenue (TTM):

$3.67M

Revenue Per Share (TTM):

$0.03

Earnings per Share:

$-0.045

Profit Margin:

-2.2803

Operating Margin (TTM):

$-2.28

Return On Assets (TTM):

$-0.60

Return On Equity (TTM):

$-1.20

Quarterly Revenue Growth (YOY):

0.23

Gross Profit(TTM):

$2.26M

Diluted Earnings Per Share (TTM):

$-0.056

RNO CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-265,796

Change To Liabilities:

$-101,298

Total Cashflow From Investing Activities:

$-265,796

Net Income:

$-5,940,742

Total Cash From Operating Activities:

$-4,493,527

Depreciation:

$364.83K

Change To Inventory:

$22.10K

Change To Account Receivables:

$441.41K

Sale Purchase Of Stock:

$-217,802

Capital Expenditures:

$230.80K

RNO Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-5,928,690

Net Income:

$-5,940,742

Gross Profit:

$2.19M

Operating Income:

$-6,013,431

Other Operating Expenses:

$686.50K

Income Tax Expense:

$12.05K

Total Revenue:

$3.29M

Total Operating Expenses:

$8.21M

Cost Of Revenue:

$1.09M

RNO Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$1.39M

Total Liabilities:

$1.25M

Total Stockholder Equity:

$4.62M

Other Current Liabilities:

$556.30K

Total Assets:

$5.87M

Common Stock:

$59.24M

Other Current Assets:

$266.74K

Retained Earnings:

$-56,166,407

Other Liabilities:

$50.97K

Good Will:

$1.57M

Other Assets:

$192.62K

Cash:

$1.42M

Total Current Liabilities:

$1.20M

Property - Plant & Equipment:

$222.16K

Net Tangible Assets:

$1.86M

Long-Term Investments:

$87.17K

Total Current Assets:

$2.61M

Net Receivables:

$594.09K

Short-Term Investments:

$3.26M

Inventory:

$336.97K

Accounts Payable:

$365.31K

Non Currrent Assets (Other):

$3.26M

Short-Term Investments:

$3.26

Non Current Liabilities Total:

$50.97K

RNO Share Price History

RNO News

20 Feb, 2020
Michael Johnson is the CEO of Rhinomed Limited (ASX:RNO). This analysis aims first to contrast CEO compensation with...
13 Dec, 2019
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
09 Dec, 2019
Global OTCQX Consumer and Resource Company Investor Presentations Now Available for On-Demand Viewing
10 Sep, 2019
The CEO of Rhinomed Limited (ASX:RNO) is Michael Johnson. This report will, first, examine the CEO compensation levels...